Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Turcot Syndrome”

64 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 64 results

Testing effectiveness (Phase 2)Ended earlyNCT02992964
What this trial is testing

Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers

Who this might be right for
Refractory or Recurrent Hypermutated MalignanciesBiallelic Mismatch Repair Deficiency (bMMRD) Positive Patients
The Hospital for Sick Children 11
Testing effectiveness (Phase 2)Active Not RecruitingNCT03767348
What this trial is testing

Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)Microsatellite Instability-High (MSI-H)Non-melanoma Skin Cancer (NMSC)+1 more
Replimune, Inc. 340
Testing effectiveness (Phase 2)Looking for participantsNCT05086692
What this trial is testing

A Beta-only IL-2 ImmunoTherapY Study

Who this might be right for
Advanced Solid TumorUnresectable Solid TumorClear Cell Renal Cell Carcinoma+34 more
Medicenna Therapeutics, Inc. 115
Early research (Phase 1)Ended earlyNCT05909995
What this trial is testing

Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors

Who this might be right for
MelanomaHepatocellular Carcinoma (HCC)Renal Cell Carcinoma (RCC)+3 more
Incyte Corporation 8
Testing effectiveness (Phase 2)Active Not RecruitingNCT03228667
What this trial is testing

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Who this might be right for
Non-Small Cell Lung CancerSmall Cell Lung CancerUrothelial Carcinoma+10 more
ImmunityBio, Inc. 40
Not applicableLooking for participantsNCT03050268
What this trial is testing

Familial Investigations of Childhood Cancer Predisposition

Who this might be right for
Acute LeukemiaAdenomatous PolyposisAdrenocortical Carcinoma+43 more
St. Jude Children's Research Hospital 1,500
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07259473
What this trial is testing

Factors Influencing Immunotherapy Response in dMMR/MSI-H Gastric/Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric / Gastroesophageal Junction AdenocarcinomaMismatch Repair Deficient or MSI-High Solid TumorsImmunotherapy
Shanghai Zhongshan Hospital 15
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06646445
What this trial is testing

Neoadjuvant Pembrolizumab With a Watch-and-wait Strategy for dMMR/MSI-H Localized Colon Cancer: PREMICES Study.

Who this might be right for
Colon Cancer
GERCOR - Multidisciplinary Oncology Cooperative Group 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT06710847
What this trial is testing

Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

Who this might be right for
Neoplasms, ColorectalSolid TumorColon Cancer+2 more
GlaxoSmithKline 14
Testing effectiveness (Phase 2)Active Not RecruitingNCT03607890
What this trial is testing

Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor

Who this might be right for
Refractory MSI - H Solid Tumors Prior of PD-(L) 1 TherapyMSI-H Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 38
Testing effectiveness (Phase 2)Looking for participantsNCT05093231
What this trial is testing

Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer

Who this might be right for
Pancreatic Cancer
Cambridge University Hospitals NHS Foundation Trust 20
Testing effectiveness (Phase 2)Looking for participantsNCT04636008
What this trial is testing

Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer

Who this might be right for
Anti-PD-1 AntibodyRadiotherapyRectal Cancer+2 more
West China Hospital 20
Testing effectiveness (Phase 2)Looking for participantsNCT03935893
What this trial is testing

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers

Who this might be right for
Gastric CancerColorectal CancerPancreatic Cancer+7 more
Udai Kammula 240
Early research (Phase 1)Ended earlyNCT06034860
What this trial is testing

Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types

Who this might be right for
Non Small Cell Lung CancerHepatocellular CarcinomaMelanoma+8 more
Molecular Templates, Inc. 15
Early research (Phase 1)WithdrawnNCT04500548
What this trial is testing

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

Who this might be right for
Constitutional Mismatch Repair Deficiency SyndromeHematopoietic and Lymphoid Cell NeoplasmLynch Syndrome+9 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Study completedNCT04439214
What this trial is testing

Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 47
Testing effectiveness (Phase 2)WithdrawnNCT04001101
What this trial is testing

Anti-PD-1 +/- RT for MSI-H Solid Tumors

Who this might be right for
Microsatellite Instability HighMismatch Repair DeficiencyColorectal Cancer
University of Colorado, Denver
Large-scale testing (Phase 3)Looking for participantsNCT05770102
What this trial is testing

DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition

Who this might be right for
MalignancyMalignant NeoplasmLymphoproliferative Disorders+7 more
Cancer Research UK 30
Not applicableNot Yet RecruitingNCT07360834
What this trial is testing

Study Aiming to Test Whether Non-invasive Liquid Biopsies Can Safely Reduce Invasive Surveillance Methods in Lynch Syndrome

Who this might be right for
Lynch Syndrome
UNICANCER 2,000
Testing effectiveness (Phase 2)Active Not RecruitingNCT02983578
What this trial is testing

Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer

Who this might be right for
Advanced Colorectal CarcinomaAdvanced Lung Non-Small Cell CarcinomaLung Non-Small Cell Carcinoma+22 more
M.D. Anderson Cancer Center 39
Load More Results